País: Canadà
Idioma: anglès
Font: Health Canada
FLUDEOXYGLUCOSE 18F
CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
V09IX04
FLUDEOXYGLUCOSE (18F)
540GBQ
SOLUTION
FLUDEOXYGLUCOSE 18F 540GBQ
INTRAVENOUS
100
Schedule C
ROENTGENOGRAPHY
Active ingredient group (AIG) number: 0152591021; AHFS:
CANCELLED POST MARKET
2020-11-30
SULPHIDE COLLOID KIT for the preparation of 99m Tc Sulphide Colloid Injection PRODUCT MONOGRAPH DESCRIPTION The kit consists of 30 mL vials, which contain the sterile, non-pyrogenic, non-radioactive ingredients necessary to produce Technetium 99m Tc Sulphide Colloid for intravenous use. The following ingredients are present in each vial 1. Sulphide Colloid Solution 'A' (The total volume of kit component is adjusted to meet the needs of the individu al customer) PER ML Sodium Thiosulfate Pentahydrate 3 mg Potassium Perrhenate 0.5 mg Gelatin 4 mg Sterile Water for Injection qs 1 mL 2. Sulphide Colloid Solution 'B' (The total volume of kit component is adjusted to meet the needs of the individu al customer) PER ML Sodium Phosphate Dibasic Heptahydrate 93 mg Sodium Phosphate Monobasic Monohydrate 8 mg Sterile Water for Injection qs 1 mL 3. 1N HCI When prepared according to the directions, the labeling is greater than 95% and remains stable throughout the useful life of preparation. No bacteriostatic agent is present. ACTION When colloidal particles of 0.1 µ or 1 µ size are injected intravenously, their distribution in the body such that 80% or 90% is captured by the phagocytic (Kupffer) cells of the liver 5 to 10% is captured by the phagocytic cells of the spleen and the remainder by the reticuloendothelium of the bone marrow. Nearly all of the colloid particles are too small to lodge in the capillary bed of the lungs. The gall bladder, GI tract, urinary bladder are likewise not visualized and therefore no organ interference occurs on the scan. INDICATIONS Technetium 99m Tc Sulphide Colloid Injection may be used to perform: i) liver and spleen imaging; ii) bone marrow imaging; and iii) lymphoscintigraphy. CONTRAINDICATIONS None known. WARNINGS The contents of the kit are NOT radioactive before preparation and are NOT to be administered directly to the patient. After the addition of Sodium Pertechnetate 99m Tc, adequate shielding of the final preparation must be maintained. Adequate studies have not yet been perform Llegiu el document complet